Current Edition

enrollment

Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces a first readout of …

Continue Reading →
clinical

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Fortuna Fix, a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells …

Continue Reading →
arthritis

New Phase 2 Data Show Treatment With Tremfya® (Guselkumab) Improved Psoriatic Arthritis Symptoms Through One Year

Janssen Research & Development, LLC (Janssen) announced today longer-term results from a Phase 2 study investigating TREMFYA® (guselkumab), the first selective antiinterleukin- (IL)-23 monoclonal antibody …

Continue Reading →